A study drug called PLX038 for brain and spinal cord tumors
Original title: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test of a new drug in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called PLX038 in adults who have a tumor of the brain or spinal cord.
Who this trial is for. This trial is for adults 18 years or older with a tumor of the brain or spinal cord. Some people in the trial must also have tumors with changes in the MYC or MYCN genes.
Where it stands. The trial is testing what the study drug PLX038 does in people with these tumors. People get the drug through a vein, and they have blood tests, imaging scans, and other tests during study visits. The trial has not reported results. The answer is not in yet.
What this means, and what it doesn't
What it could mean: If you have a brain or spinal cord tumor, you could ask your care team whether this trial might fit you. They can explain what taking part would involve. The trial team decides who can join.
What it doesn't mean: This does not mean PLX038 works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.